PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -53.86% | -220.58% | 56.53% | 34.20% | 212.25% |
| Total Depreciation and Amortization | 94.03% | 79.24% | 190.29% | 731.10% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 903.64% | 143.05% | -73.53% | -333.33% | -- |
| Change in Net Operating Assets | -1,028.37% | 141.07% | 215.90% | -92.66% | -2,175.51% |
| Cash from Operations | -2,225.91% | 36.35% | 184.75% | -17.39% | 164.32% |
| Capital Expenditure | -228.34% | -- | -- | -30,524.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 90.93% | -387.04% | -1,356.83% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -296.26% | 83.91% | -288.33% | -4,330.78% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -110.06% | -214.68% | -49.88% | -230.07% | -- |
| Issuance of Common Stock | -- | -- | -58.58% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 645.89% | 42,799.18% | -59.80% | -100.25% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5,075.41% | 251.89% | -192.33% | -116.89% | 125.78% |